san jose collage
San Jose
Serving San Jose, California (Santa Clara County)Vol. 1, No. 23
Medicine

A kidney disease that can cause kidney failure gets its first FDA-approved drug:  South San Francisco’s Gazyva put six times as many patients into full remission

Genentech’s antibody becomes the first treatment approved for primary membranous nephropathy, a rare disease in which the immune system attacks the kidneys’ filters.  It carries serious risks, including infections.

ShareFacebookXEmail
An IV bag hangs from a metal stand beside an empty pale-blue treatment chair in a sunny clinic room, with a kidney diagram on the wall.
An AI-generated illustration of an IV bag beside an empty treatment chair in a sunny clinic.  It does not show a real clinic or a real drug. — Illustration:  AI-generated

People with a rare disease that can slowly destroy their kidneys now have a treatment approved specifically for it.  The U.S. Food and Drug Administration has approved Gazyva, an antibody drug made by South San Francisco’s Genentech, for adults with primary membranous nephropathy who are at risk of getting worse, Genentech announced Nov. 15.  It is the first FDA-approved therapy for the disease.

Primary membranous nephropathy is an autoimmune disease:  the body’s immune system attacks the glomeruli, the tiny filters in the kidneys.  Protein then leaks into the urine, a sign of kidney damage called proteinuria.  Left untreated, up to 30% of patients reach kidney failure within 10 years, according to Genentech.  It is rare, with about 1.2 new cases per 100,000 people in the U.S. each year, or roughly 4,000 Americans.

What it means for patients

If you or someone in your family has primary membranous nephropathy, Gazyva is now an option to ask a kidney specialist (nephrologist) about.  In the main trial, 36.1% of patients on Gazyva reached complete remission after two years, meaning the protein leak largely stopped, compared with 5.7% of patients on tacrolimus, an older drug that suppresses the immune system.  That is more than six times as many.

Gazyva is given by infusion into a vein, and it has serious risks.  It can bring back an old hepatitis B infection, so doctors must test for hepatitis B before and during treatment.  It can also cause reactions during an infusion, serious and sometimes fatal infections, a rare and dangerous brain infection called PML, and low white blood cell counts, according to the drug’s safety information.  Patients on Gazyva may face a higher risk of severe infections than those on tacrolimus.  Genentech’s announcement did not mention the price.

How it works

Gazyva is a lab-made antibody that latches onto CD20, a protein on the surface of B cells, a type of immune cell, and helps destroy them.  Targeting B cells goes after “a critical underlying driver of disease,” said Levi Garraway, Genentech’s chief medical officer.  The drug was first approved for blood cancers and is now approved for them in 100 countries.

This is the third FDA approval of Gazyva for an immune-related kidney disease, after lupus nephritis and idiopathic nephrotic syndrome.  The FDA is also reviewing it for systemic lupus erythematosus, the most common form of lupus, with a decision expected by December 2026, Genentech said.

The study

The approval rests on the MAJESTY trial, which randomly assigned 142 adults to Gazyva or tacrolimus.  Patients and doctors knew which drug was given.  Half of the Gazyva patients reached complete or partial remission at two years, compared with 12.9% on tacrolimus, and no new safety problems turned up, Genentech said.  The results were published in the New England Journal of Medicine and presented at a European kidney meeting in June.  Details of the trial are listed at ClinicalTrials.gov.

Source:  Genentech, “Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy,” Nov. 15, 2026; ClinicalTrials.gov, MAJESTY study NCT04629248.

Drafted by AI from the linked public source. Approved by a Daily News Editor.

Sources and documents